BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38158946)

  • 41. Profile and value of FIB-4 in patients with dual chronic hepatitis C and B.
    Liu CJ; Tseng TC; Yang WT; Su TH; Yang HC; Liu CH; Chen PJ; Chen DS; Kao JH
    J Gastroenterol Hepatol; 2019 Feb; 34(2):410-417. PubMed ID: 30151861
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Advances in the treatment of hepatitis C.
    Lawrence SP
    Adv Intern Med; 2000; 45():65-105. PubMed ID: 10635046
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Economic Evaluation of the Hepatitis C Virus Treatment Extension to Early-Stage Fibrosis Patients: Evidence from the PITER Real-World Cohort.
    Ruggeri M; Coretti S; Romano F; Kondili LA; Vella S; Cicchetti A
    Value Health; 2018 Jul; 21(7):783-791. PubMed ID: 30005750
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association between age at diagnosis and degree of liver injury in hepatitis C.
    Oliveira AC; Bortotti AC; Nunes NN; El Bacha IA; Parise ER
    Braz J Infect Dis; 2014; 18(5):507-11. PubMed ID: 24907468
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
    Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
    J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy.
    Fernández-Montero JV; Barreiro P; Vispo E; Labarga P; Sánchez-Parra C; de Mendoza C; Treviño A; Soriano V
    Antivir Ther; 2014; 19(3):287-92. PubMed ID: 24192598
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Steatosis in hepatitis C virus infection. Response to anti-viral therapy.
    Szanto P; Grigorescu M; Dumitru I; Serban A
    J Gastrointestin Liver Dis; 2006 Jun; 15(2):117-24. PubMed ID: 16802005
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Liver fibrosis progression at autopsy in injecting drug users infected by hepatitis C: a longitudinal long-term cohort study.
    Kielland KB; Delaveris GJ; Rogde S; Eide TJ; Amundsen EJ; Dalgard O
    J Hepatol; 2014 Feb; 60(2):260-6. PubMed ID: 24096048
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.
    Farhang Zangneh H; Wong WWL; Sander B; Bell CM; Mumtaz K; Kowgier M; van der Meer AJ; Cleary SP; Janssen HLA; Chan KKW; Feld JJ
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1840-1849.e16. PubMed ID: 30580095
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
    Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Coinfection with hepatitis C virus and schistosomiasis: fibrosis and treatment response.
    Abdel-Rahman M; El-Sayed M; El Raziky M; Elsharkawy A; El-Akel W; Ghoneim H; Khattab H; Esmat G
    World J Gastroenterol; 2013 May; 19(17):2691-6. PubMed ID: 23674877
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients.
    Adinolfi LE; Nevola R; Guerrera B; D'Alterio G; Marrone A; Giordano M; Rinaldi L
    J Gastroenterol Hepatol; 2018 Jul; 33(7):1379-1382. PubMed ID: 29228501
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
    Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
    J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The natural history of hepatitis C virus infection.
    Al-Quaiz MN; Madani TA; Karawi MA
    Saudi Med J; 2003 Jul; 24 Suppl 2():S67-70. PubMed ID: 12897903
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Management of viral hepatitis in hematologic malignancies.
    Firpi RJ; Nelson DR
    Blood Rev; 2008 May; 22(3):117-26. PubMed ID: 18343002
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hepatitis C infection at a tertiary hospital in South Africa: Clinical presentation, non-invasive assessment of liver fibrosis, and response to therapy.
    Abuelhassan WB; Gasim GI; Ally R; Menezes C
    S Afr Med J; 2020 Aug; 110(9):920-925. PubMed ID: 32880279
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum concentrations of insulin-like growth factor-I (igf-I) as a marker of liver fibrosis in patients with chronic hepatitis C.
    Lorenzo-Zúñiga V; Bartolí R; Masnou H; Montoliu S; Morillas RM; Planas R
    Dig Dis Sci; 2007 Nov; 52(11):3245-50. PubMed ID: 17410466
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of patients with chronic hepatitis C infection in Lombardia: a report by the Lombardia Hepatitis Network.
    Aghemo A; Bruno R; Colombo M; Medagli M; Puoti M; Rizzardini G; Fagiuoli S;
    Eur Rev Med Pharmacol Sci; 2016 Dec; 20(1 Suppl):17-19. PubMed ID: 28083863
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis.
    Zeuzem S; Soriano V; Asselah T; Gane EJ; Bronowicki JP; Angus P; Lohse AW; Stickel F; Müllhaupt B; Roberts S; Schuchmann M; Manns M; Bourlière M; Buti M; Stern JO; Gallivan JP; Voss F; Sabo JP; Böcher W; Mensa FJ;
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1282-91. PubMed ID: 25512403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.